Objective: Gastric cancer is most commonly seen in patients over 50 years old and its prognosis is poor. Surgical treatments are leading treatment methods of gastric cancers. These tumors are classified as operable, resectable, inopera- ble and nonresectable regarding their surgical evaluation. Tumor markers play a role, particularly for prognosis and follow-ups. In some instances, it is only understood that patients were actually inoperable or nonresectable during surgeries. Material and Methods: A retrospective investigation was performed of 80 patients who were clinically diagnosed with operable gastric cancer and underwent surgery in our clinic. Patients’ birth dates, genders and past medical histories of neoadjuvant therapy were recorded. Localizations of tumors inside stomach were determined endoscopically and radiologically. Localizations were classified into three categories: proximal, middle and distal. Results: There were 80 patients who were included in the study and they were reviewed retrospectively. 20 of them were females and remaining 60 patients were males. Mean value of patients ages were determined as 61,21 (± 12,37). 28 of the patients were treated surgically following a neoadjuvant therapy and other 52 patients did not receive a neoadjuvant therapy prior to surgeries. Conclusion: There was no significant relationship between CEA and CA19-9 levels and the appropriate treatment options, opera- bility or unresectability of gastric cancer patients. This may be due to the retrospective nature of our study and the low number of patients included. In addition, CA19-9 levels may be more valuable for this purpose in a study with a higher patient population.